Advances in diagnosis and management of Pompe disease

1Pompe JC. Over idiopathische hypertrophie van het hart. Vereenigingsverslag van het Genootschap ter bevordering van Natuur-, Genees- en Heelkunde te Amsterdam. Vergadering van de afdeling Geneeskunde, op woensdag 18 November 1931. Ned Tijdschr Geneeskd. 1932;76:304–11. Pompe JC Over idiopathische hypertrophie van het hart. Vereenigingsverslag van het Genootschap ter bevordering van Natuur-, Genees- en Heelkunde te Amsterdam Vergadering van de afdeling Geneeskunde, op woensdag 18 November 1931. Ned Tijdschr Geneeskd 1932 76304 11Search in Google Scholar

2Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, Bossen E, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest. 2006;86(12):1208–20. doi: 10.1038/labinvest.3700484 Thurberg BL Lynch Maloney C Vaccaro C Afonso K Tsai AC Bossen E et al Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease Lab Invest 2006 86121208 20 10.1038/labinvest.370048417075580Open DOISearch in Google Scholar

3Hahn A, Schänzer A. Long-term outcome and unmet needs in infantile-onset Pompe disease. Ann Transl Med. 2019;7(13):283. doi: 10.21037/atm.2019.04.70 Hahn A Schänzer A Long-term outcome and unmet needs in infantile-onset Pompe disease Ann Transl Med 2019 713283 10.21037/atm.2019.04.70664293431392195Open DOISearch in Google Scholar

4van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332–40. doi: 10.1542/peds.112.2.332 van den Hout HM Hop W van Diggelen OP Smeitink JA Smit GP Poll-The BT et al The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature Pediatrics 2003 1122332 40 10.1542/peds.112.2.33212897283Open DOISearch in Google Scholar

5Güngör D, de Vries JM, Hop WC, Reuser AJ, van Doorn PA, van der Ploeg AT, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis. 2011;6:34. doi: 10.1186/1750-1172-6-34 Güngör D de Vries JM Hop WC Reuser AJ van Doorn PA van der Ploeg AT et al Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy Orphanet J Rare Dis 2011 634 10.1186/1750-1172-6-34313550021631931Open DOISearch in Google Scholar

6Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, et al. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128(Pt 3):671–7. doi: 10.1093/brain/awh384 Hagemans ML Winkel LP Van Doorn PA Hop WJ Loonen MC Reuser AJ et al Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients Brain 2005 128Pt 3671 7 10.1093/brain/awh38415659425Open DOISearch in Google Scholar

7Lukacs Z, Nieves Cobos P, Wenninger S, Willis TA, Guglieri M, Roberts M, et al. Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness. Neurology. 2016;87(3):295–8. doi: 10.1212/WNL.0000000000002758 Lukacs Z Nieves Cobos P Wenninger S Willis TA Guglieri M Roberts M et al Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness Neurology 2016 873295 8 10.1212/WNL.0000000000002758495527327170567Open DOISearch in Google Scholar

8Fukuhara Y, Fuji N, Yamazaki N, Hirakiyama A, Kamioka T, Seo JH, et al. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan. Mol Genet Metab Rep. 2017;14:3–9. doi: 10.1016/j.ymgmr.2017.10.009 Fukuhara Y Fuji N Yamazaki N Hirakiyama A Kamioka T Seo JH et al A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan Mol Genet Metab Rep 2017 143 9 10.1016/j.ymgmr.2017.10.009567140529124014Open DOISearch in Google Scholar

9Pompe disease GAA variant database. Available from: http://www.pompevariantdatabase.nl/pompe_mutations_list.php?orderby=aMut_ID1 Pompe disease GAA variant database Available from http://www.pompevariantdatabase.nl/pompe_mutations_list.php?orderby=aMut_ID1Search in Google Scholar

10Goldstein JL, Young SP, Changela M, Dickerson GH, Zhang H, Dai J, et al. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory. Muscle Nerve. 2009;40(1):32–6. doi: 10.1002/mus.21376 Goldstein JL Young SP Changela M Dickerson GH Zhang H Dai J et al Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory Muscle Nerve 2009 40132 6 10.1002/mus.2137619533645Open DOISearch in Google Scholar

11Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J. Methods of diagnosis of patients with Pompe disease: data from the Pompe Registry. Mol Genet Metab. 2014;113(1–2):84–91. doi: 10.1016/j.ymgme.2014.07.014 Kishnani PS Amartino HM Lindberg C Miller TM Wilson A Keutzer J Methods of diagnosis of patients with Pompe disease: data from the Pompe Registry Mol Genet Metab 2014 1131–284 91 10.1016/j.ymgme.2014.07.01425085280Open DOISearch in Google Scholar

12Anderson G, Smith VV, Malone M, Sebire NJ. Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2,500 cases from a single centre. J Clin Pathol. 2005;58(12):1305–10. doi: 10.1136/jcp.2005.027045 Anderson G Smith VV Malone M Sebire NJ Blood film examination for vacuolated lymphocytes in the diagnosis of metabolic disorders; retrospective experience of more than 2,500 cases from a single centre J Clin Pathol 2005 58121305 10 10.1136/jcp.2005.027045177078316311352Open DOISearch in Google Scholar

13Pascarella A, Terracciano C, Farina O, Lombardi L, Esposito T, Napolitano F, et al. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy. J Cell Physiol. 2018;233(8):5829–37. doi: 10.1002/jcp.26365 Pascarella A Terracciano C Farina O Lombardi L Esposito T Napolitano F et al Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy J Cell Physiol 2018 23385829 37 10.1002/jcp.2636529215735Open DOISearch in Google Scholar

14Manwaring V, Prunty H, Bainbridge K, Burke D, Finnegan N, Franses R, et al. Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases. J Inherit Metab Dis. 2012;35(2):311–6. doi: 10.1007/s10545-011-9360-2 Manwaring V Prunty H Bainbridge K Burke D Finnegan N Franses R et al Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases J Inherit Metab Dis 2012 352311 6 10.1007/s10545-011-9360-221687968Open DOISearch in Google Scholar

15Rairikar MV, Case LE, Bailey LA, Kazi ZB, Desai AK, Berrier KL, et al. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G “late-onset” GAA variant. Mol Genet Metab. 2017;122(3):99–107. doi: 10.1016/j.ymgme.2017.09.008 Rairikar MV Case LE Bailey LA Kazi ZB Desai AK Berrier KL et al Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G “late-onset” GAA variant Mol Genet Metab 2017 122399 107 10.1016/j.ymgme.2017.09.008572267528951071Open DOISearch in Google Scholar

16Yang CF, Liu HC, Hsu TR, Tsai FC, Chiang SF, Chiang CC, et al. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. Am J Med Genet A. 2014;164A(1):54–61. doi: 10.1002/ajmg.a.36197 Yang CF Liu HC Hsu TR Tsai FC Chiang SF Chiang CC et al A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment Am J Med Genet A 2014 164A154–61 10.1002/ajmg.a.3619724243590Open DOISearch in Google Scholar

17Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status afects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26–33. doi: 10.1016/j.ymgme.2009.08.003 Kishnani PS Goldenberg PC DeArmey SL Heller J Benjamin D Young S et al Cross-reactive immunologic material status afects treatment outcomes in Pompe disease infants Mol Genet Metab 2010 99126 33 10.1016/j.ymgme.2009.08.003372134019775921Open DOISearch in Google Scholar

18Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. 2012;160C(1):40–9. doi: 10.1002/ajmg.c.31319 Bali DS Goldstein JL Banugaria S Dai J Mackey J Rehder C et al Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience Am J Med Genet C Semin Med Genet 2012 160C140–9 10.1002/ajmg.c.31319327807622252923Open DOISearch in Google Scholar

19Wang Z, Okamoto P, Keutzer J. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease. Mol Genet Metab. 2014;111(2):92–100. doi: 10.1016/j.ymgme.2013.08.010 Wang Z Okamoto P Keutzer J A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease Mol Genet Metab 2014 111292 100 10.1016/j.ymgme.2013.08.01024044919Open DOISearch in Google Scholar

20Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267–88. doi: 10.1097/01.gim.0000218152.87434. f3. Erratum in: Genet Med. 2006 Jun;8(6):382. ACMG Work Group on Management of Pompe Disease [removed]; Case, Laura [corrected to Case, Laura E]. Kishnani PS Steiner RD Bali D Berger K Byrne BJ Case LE et al Pompe disease diagnosis and management guideline Genet Med 2006 85267 88 10.1097/01.gim.0000218152.87434 f3. Erratum in: Genet Med. 2006 Jun;8(6):382. ACMG Work Group on Management of Pompe Disease [removed]; Case, Laura [corrected to Case, Laura E]Open DOISearch in Google Scholar

21Musumeci O, la Marca G, Spada M, Mondello S, Danesino C, Comi GP, et al.; Italian GSD II group. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population. J Neurol Neurosurg Psychiatry. 2016;87(1):5–11. doi: 10.1136/jnnp-2014-310164 Musumeci O la Marca G Spada M Mondello S Danesino C Comi GP et al Italian GSD II group. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population J Neurol Neurosurg Psychiatry 2016 8715 11 10.1136/jnnp-2014-31016425783438Open DOISearch in Google Scholar

22Lai CJ, Hsu TR, Yang CF, Chen SJ, Chuang YC, Niu DM. Cognitive development in infantile-onset Pompe disease under very early enzyme replacement therapy. J Child Neurol. 2016;31(14):1617– 21. doi: 10.1177/0883073816665549 Lai CJ Hsu TR Yang CF Chen SJ Chuang YC Niu DM Cognitive development in infantile-onset Pompe disease under very early enzyme replacement therapy J Child Neurol 2016 31141617–21 10.1177/088307381666554927655474Open DOISearch in Google Scholar

23Yang CF, Yang CC, Liao HC, Huang LY, Chiang CC, Ho HC, et al. Very early treatment for infantile-onset Pompe disease contributes to better outcomes. J Pediatr. 2016;169:174.e1–80.e1. doi: 10.1016/j.jpeds.2015.10.078 Yang CF Yang CC Liao HC Huang LY Chiang CC Ho HC et al Very early treatment for infantile-onset Pompe disease contributes to better outcomes J Pediatr 2016 169174 e 1–80.e1 10.1016/j.jpeds.2015.10.078Open DOISearch in Google Scholar

24Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264(4):621–30. doi: 10.1007/s00415-016-8219-8 Schoser B Stewart A Kanters S Hamed A Jansen J Chan K et al Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis J Neurol 2017 2644621 30 10.1007/s00415-016-8219-8Open DOISearch in Google Scholar

25Bodamer OA, Scott CR, Giugliani R; Pompe Disease Newborn Screening Working Group. Newborn screening for pompe disease. Pediatrics. 2017;140(Suppl 1):S4–13. doi: 10.1542/peds.2016-0280C Bodamer OA Scott CR Giugliani R Pompe Disease Newborn Screening Working Group. Newborn screening for pompe disease Pediatrics 2017 140Suppl 1S4 13 10.1542/peds.2016-0280COpen DOISearch in Google Scholar

26Chien YH, Lee NC, Chen CA, Tsai FJ, Tsai WH, Shieh JY, et al. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. J Pediatr. 2015;166(4):985.e1-2–91.e1-2. doi: 10.1016/j.jpeds.2014.10.068 Chien YH Lee NC Chen CA Tsai FJ Tsai WH Shieh JY et al Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth J Pediatr 2015 1664985 e1-2–91.e1-2 10.1016/j.jpeds.2014.10.068Open DOISearch in Google Scholar

27Kronn DF, Day-Salvatore D, Hwu WL, Jones SA, Nakamura K, Okuyama T, et al. Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum. Pediatrics. 2017;140(Suppl 1):S24–45. doi: 10.1542/peds.2016-0280E Kronn DF Day-Salvatore D Hwu WL Jones SA Nakamura K Okuyama T et al Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum Pediatrics 2017 140Suppl 1S24 45 10.1542/peds.2016-0280EOpen DOISearch in Google Scholar

28Kishnani PS, Hwu WL; Pompe Disease Newborn Screening Working Group. Introduction to the newborn screening, diagnosis, and treatment for Pompe disease guidance supplement. Pediatrics. 2017;140(Suppl 1):S1–3. doi: 10.1542/peds.2016-0280B Kishnani PS Hwu WL Pompe Disease Newborn Screening Working Group. Introduction to the newborn screening, diagnosis, and treatment for Pompe disease guidance supplement Pediatrics 2017 140Suppl 1S1 3 10.1542/peds.2016-0280BOpen DOISearch in Google Scholar

29Thomas R, Kermode AR. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective. Mol Genet Metab. 2019;126(2):83–97. doi: 10.1016/j. ymgme.2018.11.011 Thomas R Kermode AR Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective Mol Genet Metab 2019 126283 97 10.1016/j.ymgme.2018.11.011Open DOISearch in Google Scholar

30Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356(9227):397–8. doi: 10.1016/s0140-6736(00)02533-2 Van den Hout H Reuser AJ Vulto AG Loonen MC Cromme-Dijkhuis A Van der Ploeg AT Recombinant human alpha-glucosidase from rabbit milk in Pompe patients Lancet 2000 3569227397 8 10.1016/s0140-6736(00)02533-2Open DOISearch in Google Scholar

31Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 2001;3(2):132–8. doi: 10.1038/gim200127 Amalfitano A Bengur AR Morse RP Majure JM Case LE Veerling DL et al Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial Genet Med 2001 32132 8 10.1038/gim200127Open DOISearch in Google Scholar

32Broomfield A, Fletcher J, Davison J, Finnegan N, Fenton M, Chikermane A, et al. Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy. J Inherit Metab Dis. 2016;39(2):261–71. doi: 10.1007/s10545-015-9898-5 Broomfield A Fletcher J Davison J Finnegan N Fenton M Chikermane A et al Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy J Inherit Metab Dis 2016 392261 71 10.1007/s10545-015-9898-526497565Open DOISearch in Google Scholar

33van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med. 2010;362(15):1396–406. doi: 10.1056/NEJMoa0909859 van der Ploeg AT Clemens PR Corzo D Escolar DM Florence J Groeneveld GJ et al A randomized study of alglucosidase alfa in late-onset Pompe’s disease N Engl J Med 2010 362151396 406 10.1056/NEJMoa090985920393176Open DOISearch in Google Scholar

34Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, Favejee MM, van der Meijden JC, et al. Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study. Neurology. 2017;89(23):2365–73. doi: 10.1212/WNL.0000000000004711 Kuperus E Kruijshaar ME Wens SCA de Vries JM Favejee MM van der Meijden JC et al Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study Neurology 2017 89232365 73 10.1212/WNL.000000000000471129117951Open DOISearch in Google Scholar

35Kazi ZB, Desai AK, Berrier KL, Troxler RB, Wang RY, Abdul-Rahman OA, et al. Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight. 2017;2(16):e94328. doi: 10.1172/jci.insight.94328 Kazi ZB Desai AK Berrier KL Troxler RB Wang RY Abdul-Rahman OA et al Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease JCI Insight 2017 216e94328 10.1172/jci.insight.94328562190928814660Open DOISearch in Google Scholar

36Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012;14(1):135–42. doi: 10.1038/gim.2011.4 Messinger YH Mendelsohn NJ Rhead W Dimmock D Hershkovitz E Champion M et al Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease Genet Med 2012 141135 42 10.1038/gim.2011.4371122422237443Open DOISearch in Google Scholar

37Koeberl DD, Austin S, Case LE, Smith EC, Buckley AF, Young SP, et al. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease. FASEB J. 2014;28(5):2171–6. doi: 10.1096/fj.13-241893 Koeberl DD Austin S Case LE Smith EC Buckley AF Young SP et al Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease FASEB J 2014 2852171 6 10.1096/fj.13-24189324443373Open DOISearch in Google Scholar

38Chien YH, Hwu WL, Lee NC, Tsai FJ, Koeberl DD, Tsai WH, et al. Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease. Mol Genet Metab Rep. 2017;11:31–5. doi: 10.1016/j.ymgmr.2017.04.004 Chien YH Hwu WL Lee NC Tsai FJ Koeberl DD Tsai WH et al Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease Mol Genet Metab Rep 2017 1131 5 10.1016/j.ymgmr.2017.04.004540627528480166Open DOISearch in Google Scholar

39NIH. Clinical Trials Database. Available from: www.clinicaltrials.gov NIH. Clinical Trials Database Available from www.clinicaltrials.govSearch in Google Scholar

40Puzzo F, Colella P, Biferi MG, Bali D, Paulk NK, Vidal P, et al. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase. Sci Transl Med. 2017;9(418):eaam6375. doi: 10.1126/scitranslmed.aam6375 Puzzo F Colella P Biferi MG Bali D Paulk NK Vidal P et al Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase Sci Transl Med 2017 9418 10.1126/scitranslmed.aam6375582661129187643Open DOISearch in Google Scholar

41Kishnani PS, Koeberl DD. Liver depot gene therapy for Pompe disease. Ann Transl Med. 2019;7(13):288. doi: 10.21037/ atm.2019.05.02 Kishnani PS Koeberl DD Liver depot gene therapy for Pompe disease Ann Transl Med 2019 713288 10.21037/atm.2019.05.02664293531392200Open DOISearch in Google Scholar

42Ronzitti G, Collaud F, Laforet P, Mingozzi F. Progress and challenges of gene therapy for Pompe disease. Ann Transl Med. 2019;7(13):287. doi: 10.21037/atm.2019.04.67 Ronzitti G Collaud F Laforet P Mingozzi F Progress and challenges of gene therapy for Pompe disease Ann Transl Med 2019 713287 10.21037/atm.2019.04.67664294131392199Open DOISearch in Google Scholar

43Swift G, Cleary M, Grunewald S, Lozano S, Ryan M, Davison J. Swallow prognosis and follow-up protocol in infantile onset Pompe disease. JIMD Rep. 2017;33:11–7. doi: 10.1007/8904_2016_576 Swift G Cleary M Grunewald S Lozano S Ryan M Davison J Swallow prognosis and follow-up protocol in infantile onset Pompe disease JIMD Rep 2017 3311 7 10.1007/8904_2016_576541344927344650Open DOISearch in Google Scholar

44Figueroa-Bonaparte S, Llauger J, Segovia S, Belmonte I, Pedrosa I, Montiel E, et al. Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study. Sci Rep. 2018;8(1):10898. doi: 10.1038/s41598-018-29170-7 Figueroa-Bonaparte S Llauger J Segovia S Belmonte I Pedrosa I Montiel E et al Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study Sci Rep 2018 8110898 10.1038/s41598-018-29170-7605200230022036Open DOISearch in Google Scholar

45Tarallo A, Carissimo A, Gatto F, Nusco E, Toscano A, Musumeci O, et al. microRNAs as biomarkers in Pompe disease. Genet Med. 2019;21(3):591–600. doi: 10.1038/s41436-018-0103-8 Tarallo A Carissimo A Gatto F Nusco E Toscano A Musumeci O et al microRNAs as biomarkers in Pompe disease Genet Med 2019 213591 600 10.1038/s41436-018-0103-829997386Open DOISearch in Google Scholar

46Carrasco-Rozas A, Fernández-Simón E, Lleixà MC, Belmonte I, Pedrosa-Hernandez I, Montiel-Morillo E, et al. Identification of serum microRNAs as potential biomarkers in Pompe disease. Ann Clin Transl Neurol. 2019;6(7):1214–24. doi: 10.1002/acn3.50800 Carrasco-Rozas A Fernández-Simón E Lleixà MC Belmonte I Pedrosa-Hernandez I Montiel-Morillo E et al Identification of serum microRNAs as potential biomarkers in Pompe disease Ann Clin Transl Neurol 2019 671214 24 10.1002/acn3.50800664963831353854Open DOISearch in Google Scholar

47Schüller A, Wenninger S, Strigl-Pill N, Schoser B. Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet C Semin Med Genet. 2012;160C(1):80–88. doi: 10.1002/ ajmg.c.31322 Schüller A Wenninger S Strigl-Pill N Schoser B Toward deconstructing the phenotype of late-onset Pompe disease Am J Med Genet C Semin Med Genet 2012 160C180–88 10.1002/ajmg.c.3132222253010Open DOISearch in Google Scholar

48Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, et al. The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab. 2017;120(3): 163–72. doi: 10.1016/j.ymgme.2016.12.004 Chan J Desai AK Kazi ZB Corey K Austin S Hobson-Webb LD et al The emerging phenotype of late-onset Pompe disease: a systematic literature review Mol Genet Metab 2017 1203 163 72 10.1016/j.ymgme.2016.12.00428185884Open DOISearch in Google Scholar

49Mori M, Bailey LA, Estrada J, Rehder CW, Li JS, Rogers JG, et al. Severe cardiomyopathy as the isolated presenting feature in an adult with late-onset pompe disease: a case report. JIMD Rep. 2017;31:79–83. doi: 10.1007/8904_2016_563 Mori M Bailey LA Estrada J Rehder CW Li JS Rogers JG et al Severe cardiomyopathy as the isolated presenting feature in an adult with late-onset pompe disease: a case report JIMD Rep 2017 3179 83 10.1007/8904_2016_563538864227142047Open DOISearch in Google Scholar

50Bernstein DL, Bialer MG, Mehta L, Desnick RJ. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. Mol Genet Metab. 2010;101(2–3):130–3. doi: 10.1016/j.ymgme.2010.06.003. Bernstein DL Bialer MG Mehta L Desnick RJ Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy A report of three later-onset patients. Mol Genet Metab 2010 1012–3130 3 10.1016/j.ymgme.2010.06.00320638881Open DOISearch in Google Scholar

51Ajay D, McNamara ER, Austin S, Wiener JS, Kishnani P. Lower urinary tract symptoms and incontinence in children with pompe disease. JIMD Rep. 2016;28:59–67. doi: 10.1007/8904_2015_492 Ajay D McNamara ER Austin S Wiener JS Kishnani P Lower urinary tract symptoms and incontinence in children with pompe disease JIMD Rep 2016 2859 67 10.1007/8904_2015_492505919726537578Open DOISearch in Google Scholar

52Guevara-Campos J, González-Guevara L, Cauli O. Skeletal alterations, developmental delay and new mutations in juvenile-onset Pompe disease. Neuromuscul Disord. 2019;29(3):192–7. doi: 10.1016/j.nmd.2018.11.013 Guevara-Campos J González-Guevara L Cauli O. Skeletal alterations, developmental delay and new mutations in juvenile-onset Pompe disease Neuromuscul Disord 2019 293192 7 10.1016/j.nmd.2018.11.01330595407Open DOISearch in Google Scholar

53Hensel O, Hanisch F, Stock K, Stoevesandt D, Deschauer M, Müller T. Morphology and function of cerebral arteries in adults with Pompe disease. JIMD Rep. 2015;20:27–33. doi: 10.1007/8904_2014_385 Hensel O Hanisch F Stock K Stoevesandt D Deschauer M Müller T Morphology and function of cerebral arteries in adults with Pompe disease JIMD Rep 2015 2027 33 10.1007/8904_2014_385437512325614309Open DOISearch in Google Scholar

54Quenardelle V, Bataillard M, Bazin D, Lannes B, Wolff V, Echaniz-Laguna A. Pompe disease presenting as an isolated generalized dilative arteriopathy with repeated brain and kidney infarcts. J Neurol. 2015;262(2):473–5. doi: 10.1007/s00415-014-7582-6 Quenardelle V Bataillard M Bazin D Lannes B Wolff V Echaniz-Laguna A Pompe disease presenting as an isolated generalized dilative arteriopathy with repeated brain and kidney infarcts J Neurol 2015 2622473 5 10.1007/s00415-014-7582-625451853Open DOISearch in Google Scholar

55Pena LD, Proia AD, Kishnani PS. Postmortem findings and clinical correlates in individuals with infantile-onset Pompe disease. JIMD Rep. 2015;23:45–54. doi: 10.1007/8904_2015_426 Pena LD Proia AD Kishnani PS Postmortem findings and clinical correlates in individuals with infantile-onset Pompe disease JIMD Rep 2015 2345 54 10.1007/8904_2015_426448490025763511Open DOISearch in Google Scholar

56Broomfield A, Fletcher J, Hensman P, Wright R, Prunty H, Pavaine J, et al. Rapidly progressive white matter involvement in early childhood: the expanding phenotype of infantile onset Pompe? JIMD Rep. 2018;39:55–62. doi: 10.1007/8904_2017_46 Broomfield A Fletcher J Hensman P Wright R Prunty H Pavaine J et al Rapidly progressive white matter involvement in early childhood: the expanding phenotype of infantile onset Pompe? JIMD Rep 2018 3955 62 10.1007/8904_2017_46595389028726123Open DOISearch in Google Scholar

57van Capelle CI, Goedegebure A, Homans NC, Hoeve HL, Reuser AJ, van der Ploeg AT. Hearing loss in Pompe disease revisited: results from a study of 24 children. J Inherit Metab Dis. 2010;33(5):597–602. doi: 10.1007/s10545-010-9144-0 van Capelle CI Goedegebure A Homans NC Hoeve HL Reuser AJ van der Ploeg AT Hearing loss in Pompe disease revisited: results from a study of 24 children J Inherit Metab Dis 2010 335597 602 10.1007/s10545-010-9144-0294656620596893Open DOISearch in Google Scholar

58Kamphoven JH, de Ruiter MM, Winkel LP, Van den Hout HM, Bijman J, De Zeeuw CI, et al. Hearing loss in infantile Pompe’s disease and determination of underlying pathology in the knockout mouse. Neurobiol Dis. 2004;16(1):14–20. doi: 10.1016/j. nbd.2003.12.018 Kamphoven JH de Ruiter MM Winkel LP Van den Hout HM Bijman J De Zeeuw CI et al Hearing loss in infantile Pompe’s disease and determination of underlying pathology in the knockout mouse Neurobiol Dis 2004 16114 20 10.1016/j.nbd.2003.12.01815207257Open DOISearch in Google Scholar

59Ebbink BJ, Poelman E, Aarsen FK, Plug I, Régal L, Muentjes C, et al. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain. Dev Med Child Neurol. 2018;60(6):579–86. doi: 10.1111/dmcn.13740 Ebbink BJ Poelman E Aarsen FK Plug I Régal L Muentjes C et al Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain Dev Med Child Neurol 2018 606579 86 10.1111/dmcn.1374029573408Open DOISearch in Google Scholar

60Spiridigliozzi GA, Keeling LA, Stefanescu M, Li C, Austin S, Kishnani PS. Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: a longitudinal follow-up. Mol Genet Metab. 2017;121(2):127–37. doi: 10.1016/j. ymgme.2017.04.014 Spiridigliozzi GA Keeling LA Stefanescu M Li C Austin S Kishnani PS Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: a longitudinal follow-up Mol Genet Metab 2017 1212127 37 10.1016/j.ymgme.2017.04.014598583328495044Open DOISearch in Google Scholar

61Musumeci O, Marino S, Granata F, Morabito R, Bonanno L, Brizzi T, et al. Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis. Eur J Neurol. 2019;26(3):442–51, e34–5. doi: 10.1111/ ene.13835 Musumeci O Marino S Granata F Morabito R Bonanno L Brizzi T et al Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis Eur J Neurol 2019 263442 51 e34–5 10.1111/ene.1383530312517Open DOISearch in Google Scholar

62Schneider I, Hensel O, Zierz S. White matter lesions in treated late onset Pompe disease are not different to matched controls. Mol Genet Metab. 2019;127(2):128–31. doi: 10.1016/j. ymgme.2019.05.007 Schneider I Hensel O Zierz S White matter lesions in treated late onset Pompe disease are not different to matched controls Mol Genet Metab 2019 1272128 31 10.1016/j.ymgme.2019.05.00731153821Open DOISearch in Google Scholar

63Byrne BJ, Fuller DD, Smith BK, Clement N, Coleman K, Cleaver B, et al. Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy. Ann Transl Med. 2019;7(13):290. doi: 10.21037/atm.2019.05.56 Byrne BJ Fuller DD Smith BK Clement N Coleman K Cleaver B et al Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy Ann Transl Med 2019 713290 10.21037/atm.2019.05.56664292931392202Open DOISearch in Google Scholar